Andrea Riccardo Filippi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1033699/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer, 2010, 68, 72-77.	0.9	268
2	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. Oncologist, 2012, 17, 1100-1107.	1.9	185
3	COVID-19: Global radiation oncology's targeted response for pandemic preparedness. Clinical and Translational Radiation Oncology, 2020, 22, 55-68.	0.9	183
4	Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2018, 101, 521-529.	0.4	138
5	Stereotactic body radiation therapy for lung metastases. Lung Cancer, 2012, 75, 77-81.	0.9	133
6	Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. International Journal of Radiation Oncology Biology Physics, 2020, 107, 597-599.	0.4	127
7	Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiation Oncology, 2012, 7, 186.	1.2	96
8	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood, 2019, 133, 237-245.	0.6	85
9	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncológica, 2012, 51, 618-623.	0.8	76
10	Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: An Italian multicenter observational study. Lung Cancer, 2014, 84, 248-253.	0.9	73
11	Whey protein isolate supplementation improves body composition, muscle strength, and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy. Cancer Medicine, 2019, 8, 6923-6932.	1.3	67
12	Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study. International Journal of Radiation Oncology Biology Physics, 2015, 91, 524-529.	0.4	64
13	Stereotactic body radiotherapy for early stage lung cancer: History and updated role. Lung Cancer, 2015, 90, 388-396.	0.9	62
14	Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncológica, 2009, 48, 571-577.	0.8	60
15	Total marrow and total lymphoid irradiation in bone marrow transplantation for acute leukaemia. Lancet Oncology, The, 2020, 21, e477-e487.	5.1	57
16	Optimized Volumetric Modulated Arc Therapy Versus 3D-CRT for Early Stage Mediastinal Hodgkin Lymphoma Without Axillary Involvement: A Comparison of Second Cancers and Heart Disease Risk. International Journal of Radiation Oncology Biology Physics, 2015, 92, 161-168.	0.4	55
17	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiotherapy and Oncology, 2017, 123, 182-188.	0.3	55
18	Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer. Clinical Oncology, 2016, 28, 505-512.	0.6	50

#	Article	IF	CITATIONS
19	Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases. Technology in Cancer Research and Treatment, 2014, 13, 37-45.	0.8	49
20	Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1426-1433.	0.5	49
21	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 370-375.	0.4	46
22	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. Radiotherapy and Oncology, 2016, 120, 1-12.	0.3	44
23	COVID-19 outbreak and cancer radiotherapy disruption in Italy: Survey endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiotherapy and Oncology, 2020, 149, 89-93.	0.3	43
24	Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leukemia and Lymphoma, 2013, 54, 1183-1187.	0.6	41
25	The "BUONCIORNO―Project: Burnout Syndrome Among Young Italian Radiation Oncologists. Cancer Investigation, 2013, 31, 522-528.	0.6	41
26	Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiation Oncology Journal, 2015, 33, 57.	0.7	41
27	Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer, 2015, 89, 350-356.	0.9	37
28	Radiation Therapy in Primary Mediastinal B-Cell Lymphoma With Positron Emission Tomography Positivity After Rituximab Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 311-316.	0.4	35
29	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.4	35
30	Hypericum perforatum and neem oil for the management of acute skin toxicity in head and neck cancer patients undergoing radiation or chemo-radiation: a single-arm prospective observational study. Radiation Oncology, 2014, 9, 297.	1.2	33
31	Once-Weekly Hypofractionated Whole-Breast Radiotherapy After Breast-Conserving Surgery in Older Patients: A Potential Alternative Treatment Schedule to Daily 3-Week Hypofractionation. Clinical Breast Cancer, 2015, 15, 270-276.	1.1	33
32	Radiation therapy for older patients with brain tumors. Radiation Oncology, 2017, 12, 101.	1.2	32
33	Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. Radiotherapy and Oncology, 2019, 138, 52-58.	0.3	32
34	Late Toxicity in Children Undergoing Hematopoietic Stem Cell Transplantation with TBI-containing Conditioning Regimens for Hematological Malignancies. Strahlentherapie Und Onkologie, 2009, 185, 17-20.	1.0	31
35	Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. Cancer Treatment Reviews, 2015, 41, 511-518.	3.4	31
36	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. Radiation Oncology, 2020, 15, 92.	1.2	31

Andrea Riccardo Filippi

#	Article	IF	CITATIONS
37	Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. Journal of Radiation Research, 2016, 57, i58-i68.	0.8	30
38	Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults. International Journal of Radiation Oncology Biology Physics, 2018, 100, 17-20.	0.4	29
39	Efficacy and Safety of Tadalafil 20mg on Demand vs. Tadalafil 5mg Once-a-Day in the Treatment of Post-Radiotherapy Erectile Dysfunction in Prostate Cancer Men: A Randomized Phase II Trial. Journal of Sexual Medicine, 2010, 7, 2851-2859.	0.3	28
40	Interobserver variability of clinical target volume delineation in supra-diaphragmatic Hodgkin's disease. Strahlentherapie Und Onkologie, 2011, 187, 357-366.	1.0	28
41	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 1077-1083.	0.4	28
42	Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. Acta Oncológica, 2020, 59, 1224-1234.	0.8	27
43	COVID-19 Outbreak and Cancer Radiotherapy Disruption in Lombardy, Northern Italy. Clinical Oncology, 2020, 32, e160-e161.	0.6	27
44	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. Radiation Oncology, 2017, 12, 200.	1.2	26
45	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1600-1607.	2.0	25
46	The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer. Radiologia Medica, 2013, 118, 660-678.	4.7	25
47	Comparison of Gafchromic EBT2 and EBT3 for patient-specific quality assurance: Cranial stereotactic radiosurgery using volumetric modulated arc therapy with multiple noncoplanar arcs. Medical Physics, 2013, 40, 082105.	1.6	25
48	Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins. Radiotherapy and Oncology, 2018, 127, 481-486.	0.3	25
49	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. Journal of Thoracic Disease, 2018, 10, S1461-S1467.	0.6	25
50	Is Clinical Radiosensitivity a Complex Genetically Controlled Event?. Tumori, 2006, 92, 87-91.	0.6	24
51	Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center. European Journal of Surgical Oncology, 2020, 46, 15-23.	0.5	24
52	Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers, 2020, 12, 1186.	1.7	24
53	Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation. Radiation Oncology, 2007, 2, 15.	1.2	23
54	A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 744956.	1.3	22

#	Article	IF	CITATIONS
55	Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?. Reports of Practical Oncology and Radiotherapy, 2014, 19, 275-279.	0.3	21
56	Prognostic Role of Pre–Radiation Therapy 18F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1239-1243.	0.4	20
57	Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiation Oncology, 2020, 15, 62.	1.2	20
58	Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Radiation Oncology, 2013, 3, 216-222.	1.1	19
59	Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 14-22.	0.2	19
60	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	3.4	19
61	Postoperative Radiotherapy for Patients With Completely Resected Pathologic N2 Non–Small-Cell Lung Cancer: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 194-199.	1.1	18
62	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori, 2013, 99, 637-649.	0.6	18
63	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 144-152.	0.4	18
64	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. Expert Review of Anticancer Therapy, 2017, 17, 347-356.	1.1	18
65	The "PROCAINA (PROstate CAncer INdication Attitudes) Project―(Part II) — A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. Radiologia Medica, 2013, 118, 1220-1239.	4.7	17
66	Radiomics features as predictive and prognostic biomarkers in NSCLC. Expert Review of Anticancer Therapy, 2021, 21, 257-266.	1.1	17
67	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology Biology Physics, 2019, 104, 522-529.	0.4	16
68	The prognostic impact of BIA-derived fat-free mass index in patients with cancer. Clinical Nutrition, 2021, 40, 3901-3907.	2.3	16
69	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. Medical Oncology, 2013, 30, 729.	1.2	15
70	In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. Bone Marrow Transplantation, 2013, 48, 908-914.	1.3	15
71	Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study. Clinical and Translational Oncology, 2016, 18, 1003-1010.	1.2	15
72	1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Annals of Oncology, 2021, 32, S939-S940.	0.6	15

#	Article	IF	CITATIONS
73	Total Body Irradiation in Haematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: Review of the Literature and Future Directions. Frontiers in Pediatrics, 2021, 9, 774348.	0.9	15
74	The INTER-ROMA Project - a Survey among Italian Radiation Oncologists on Their Approach to the Treatment of Bone Metastases. Tumori, 2011, 97, 177-184.	0.6	14
75	New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Review of Anticancer Therapy, 2013, 13, 1145-1155.	1.1	14
76	Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma. Radiologia Medica, 2016, 121, 873-881.	4.7	14
77	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Advances, 2021, 5, 4504-4514.	2.5	14
78	Impact of the observers' experience on daily prostate localization accuracy in ultrasoundâ€based IGRT with the Clarity platform. Journal of Applied Clinical Medical Physics, 2014, 15, 168-173.	0.8	13
79	Interobserver variability in clinical target volume delineation for primary mediastinal B-cell lymphoma. Practical Radiation Oncology, 2015, 5, 383-389.	1.1	13
80	No differences in radiological changes after 3D conformal <i>vs</i> VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer. British Journal of Radiology, 2017, 90, 20170143.	1.0	13
81	To a new normal in radiation oncology: looking back and planning forward. Tumori, 2020, 106, 440-444.	0.6	13
82	Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab. Clinical Lung Cancer, 2020, 21, e547-e550.	1.1	13
83	The 8th UICC/AJCC TNM edition for non-small cell lung cancer staging: getting off to a flying start?. Annals of Translational Medicine, 2019, 7, S205-S205.	0.7	13
84	Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World Journal of Urology, 2013, 31, 411-415.	1.2	12
85	Salvage External Beam Radiotherapy for Recurrent Prostate Adenocarcinoma after High-Intensity Focused Ultrasound as Primary Treatment. Urologia Internationalis, 2013, 90, 288-293.	0.6	12
86	Three-Dimensional Ultrasound-Based Image-Guided Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Results of a Consecutive Case Series. Cancer Investigation, 2015, 33, 23-28.	0.6	12
87	LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016041.	0.5	12
88	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. British Journal of Radiology, 2016, 89, 20150983.	1.0	12
89	Optimal Therapy for Early-Stage Hodgkin's Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy. Current Oncology Reports, 2017, 19, 34.	1.8	12
90	Brain Metastases from Lung Cancer: Is MET an Actionable Target?. Cancers, 2019, 11, 271.	1.7	12

#	Article	IF	CITATIONS
91	79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, S738-S739.	0.5	12
92	The Role of Stereotactic Ablative Radiotherapy in Oncological and Non-Oncological Clinical Settings: Highlights from the 7 th Meeting of AIRO – Young Members Working Group (AIRO Giovani). Tumori, 2014, 100, e214-e229.	0.6	12
93	Treatment options in skeletal localizations of hairy cell leukemia: A systematic review on the role of radiation therapy. American Journal of Hematology, 2007, 82, 1017-1021.	2.0	11
94	A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group). Reports of Practical Oncology and Radiotherapy, 2012, 17, 259-261.	0.3	11
95	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Medical Oncology, 2013, 30, 581.	1.2	11
96	¹²⁵ I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience. Tumori, 2013, 99, 83-87.	0.6	11
97	Is clinical radiosensitivity a complex genetically controlled event?. Tumori, 2006, 92, 87-91.	0.6	11
98	Peripheral blood complete remission after splenic irradiation in Mantle-Cell Lymphoma with 11q22-23 deletion and ATM inactivation. Radiation Oncology, 2006, 1, 35.	1.2	10
99	Combination of novel systemic agents and radiotherapy for solid tumors – Part II: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 104-119.	0.784314 2.0	rgBT /Overlo 10
100	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219.	4.7	10
101	Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence. Cancers, 2021, 13, 3746.	1.7	10
102	The INTER-ROMA projecta survey among Italian radiation oncologists on their approach to the treatment of bone metastases. Tumori, 2011, 97, 177-84.	0.6	10
103	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1955-1960.	1.2	9
104	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.3	9
105	Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series. Clinical and Translational Oncology, 2021, 23, 364-371.	1.2	9
106	A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin's Lymphoma. Critical Reviews in Oncology/Hematology, 2021, 167, 103437.	2.0	9
107	Management of prostate cancer radiotherapy during the COVID-19 pandemic: A necessary paradigm change. Cancer Treatment and Research Communications, 2021, 27, 100331.	0.7	9
108	Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1111-1116.	1.2	8

#	Article	IF	CITATIONS
109	PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. Annals of Oncology, 2019, 30, ii37.	0.6	8
110	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clinical Lung Cancer, 2021, 22, e767-e773.	1.1	8
111	Efficacy and Safety of Stereotactic Ablative Radiotherapy in Patients with Previous Pneumonectomy. Tumori, 2015, 101, 148-153.	0.6	7
112	What do radiation oncologists require for future advancements in lung SBRT?. Physica Medica, 2017, 44, 150-156.	0.4	7
113	Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian) Tj ETQq1 1 Reviews in Oncology/Hematology, 2019, 134, 87-103.).784314 2.0	rgBT /Over o 7
114	Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 159, 103242.	2.0	7
115	Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives. Cancers, 2021, 13, 3744.	1.7	7
116	1251 brachytherapy for localized prostate cancer: a single institution experience. Tumori, 2013, 99, 83-7.	0.6	7
117	Eyelid Localization in Mantle Cell Lymphoma: Long-Lasting Complete Remission after Surface Brachytherapy. Tumori, 2009, 95, 385-388.	0.6	6
118	The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project. Technology in Cancer Research and Treatment, 2016, 15, 365-376.	0.8	6
119	Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics―study on stage III unresectable NSCLC. Insights Into Imaging, 2022, 13, 38.	1.6	6
120	Polyostotic Sclerosing Histiocytosis (Erdheim-Chester Disease) Treated with Combined Vertebroplasty and Radiation Therapy. Tumori, 2010, 96, 633-636.	0.6	5
121	Back to (new) normality—A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2. Medical Oncology, 2020, 37, 108.	1.2	5
122	COVID-19 safe and fully operational radiotherapy: An AIRO survey depicting the Italian landscape at the dawn of phase 2. Radiotherapy and Oncology, 2021, 155, 120-122.	0.3	5
123	The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110258.	1.4	5
124	Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study. BMC Cancer, 2021, 21, 762.	1.1	5
125	Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach. International Journal of Molecular Sciences, 2021, 22, 9014.	1.8	5
126	â€~Le Roi est mort, vive le Roi': new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	5

#	Article	IF	CITATIONS
127	Hypoxia and tumor response to irradiation. Rays, 2002, 27, 175-9.	0.2	5
128	An integrated approach to cardioprotection in lymphomas. Lancet Haematology,the, 2022, 9, e445-e454.	2.2	5
129	Role of modern radiation therapy in early stage Hodgkin's lymphoma: A young radiation oncologists' perspective. Reports of Practical Oncology and Radiotherapy, 2012, 17, 246-250.	0.3	4
130	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.1	4
131	Emerging treatment options in the management of non-small cell lung cancer. Lung Cancer: Targets and Therapy, 2011, 2, 11.	1.3	3
132	Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1141-1147.	1.2	3
133	THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN'S LYMPHOMA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014035.	0.5	3
134	Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4031-S4033.	0.6	3
135	A Prospective, Observational Study Evaluating Early Subclinical Cardiotoxicity with Global Longitudinal Strain Imaging in Lymphoma Patients Treated with Chemotherapy +/- Mediastinal Radiation Therapy: The CARDIOCARE Project. International Journal of Radiation Oncology Biology Physics, 2018, 102, S88.	0.4	3
136	Renewed interest for lowâ€dose radiation therapy in follicular lymphomas: From biology to clinical applications. Hematological Oncology, 2018, 36, 723-732.	0.8	3
137	The growth of non-solid neoplastic lung nodules is associated with low PD L1 expression, irrespective of sampling technique. Journal of Translational Medicine, 2020, 18, 54.	1.8	3
138	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. Radiotherapy and Oncology, 2021, 155, e20-e21.	0.3	3
139	Recent advancement on PD-L1 expression quantification: the radiologist perspective on CT-guided FNAC. Diagnostic and Interventional Radiology, 2021, 27, 214-218.	0.7	3
140	95TiP DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy. Journal of Thoracic Oncology, 2021, 16, S747.	0.5	3
141	Innovative technologies in thoracic radiation therapy for lung cancer. Translational Lung Cancer Research, 2012, 1, 263-8.	1.3	3
142	DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy. Future Oncology, 2021, 17, 4657-4663.	1.1	3
143	A Case of Bone Involvement in Hairy Cell Leukemia Successfully Treated with Radiation Therapy. Tumori, 2006, 92, 366-369.	0.6	2
144	In Reply to Adams and Kwee. International Journal of Radiation Oncology Biology Physics, 2015, 93, 725-726.	0.4	2

#	Article	IF	CITATIONS
145	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	0.6	2
146	In Reply to Scarpelli et al. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1396.	0.4	2
147	Low-dose radiotherapy for extranodal marginal zone B lymphoma of the lip: Case report and literature review. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 76-81.	0.6	2
148	Immunonutrition in head and neck cancer patients undergoing chemoradiotherapy: an alternative approach for overcoming potential bias. American Journal of Clinical Nutrition, 2021, 113, 1053-1054.	2.2	2
149	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	0.6	2
150	Advanced Radiotherapy Techniques for Mediastinal Lymphomas: Results from an Italian Survey. Hemato, 2021, 2, 496-504.	0.2	2
151	Comprehensive metastatic ablation in advanced NSCLC through biology-guided radiotherapy – A path forward?. Lung Cancer, 2021, 162, 203-206.	0.9	2
152	Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era. Critical Reviews in Oncology/Hematology, 2022, 174, 103684.	2.0	2
153	The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists. Tumori, 2014, 100, e236-42.	0.6	2
154	OC-0383: Reduced cardiac risk in Hodgkin lymphoma patients treated with a full arc VMAT compared to b-VMAT. Radiotherapy and Oncology, 2018, 127, S195-S196.	0.3	1
155	Extranodal Marginal Zone Lymphoma. , 2017, , 55-71.		1
156	Large cohort observational study integrates current knowledge on changes in outcome for melanoma brain metastases in tyrosine kinase inhibitor (TKI)-immunotherapy era. Translational Cancer Research, 2018, 7, S735-S737.	0.4	1
157	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the †radio talk' webinars. Expert Review of Anticancer Therapy, 2022, 22, 549-559.	1.1	1
158	If Subclinical Turns into Suboptimal. Tumori, 2009, 95, 268-269.	0.6	0
159	Radiation therapy in locally advanced non-small-cell lung cancer: an overview of dose/fractionation strategies to improve outcomes. Lung Cancer Management, 2012, 1, 227-235.	1.5	Ο
160	Which radiation therapy schedule in combination with chemotherapy for locally advanced NSCLC?. Lung Cancer Management, 2015, 4, 271-278.	1.5	0
161	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Multi-Institutional Pooled Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, E485-E486.	0.4	0
162	PO-0712: Stereotactic body radiotherapy in the treatment of inoperable hepatocellular carcinoma. Radiotherapy and Oncology, 2016, 119, S333.	0.3	0

Andrea Riccardo Filippi

#	Article	IF	CITATIONS
163	EP-1228: Pulmonary toxicity after 3D-CRT or VMAT-based stereotactic radiotherapy for early stage lung cancer. Radiotherapy and Oncology, 2016, 119, S581-S582.	0.3	0
164	PO-0849: Heart structures sparing through volumetric modulated arc therapy in mediastinal Hodgkin lymphoma. Radiotherapy and Oncology, 2016, 119, S404-S405.	0.3	0
165	PV-0279: Role of IFRT prior or after autologous stem cell rescue for refractory or relapsed Hodgkin lymphoma. Radiotherapy and Oncology, 2016, 119, S130-S131.	0.3	0
166	PV-0045: Estimation of internal risk volume for coronary arteries after motion evaluation with ECG-gated CT. Radiotherapy and Oncology, 2017, 123, S19-S20.	0.3	0
167	Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e683.	0.4	0
168	Stereotactic radiotherapy in previously treated lung cancers—what are the risks?. Therapeutic Radiology and Oncology, 0, 3, 11-11.	0.2	0
169	In reply to Drs Magrini, Mazzola, Greco, Alongi, Buglione. Clinical and Translational Radiation Oncology, 2020, 22, 88-89.	0.9	0
170	OC-0207 Long-term results of peri-transplant RT in Hodgkin's lymphomas: results from a multi-center study. Radiotherapy and Oncology, 2021, 161, S139-S140.	0.3	0
171	Validation of a new prognostic body composition parameter in cancer patients Journal of Clinical Oncology, 2019, 37, 11597-11597.	0.8	0
172	If subclinical turns into suboptimal. Tumori, 2009, 95, 268-9; author reply 269.	0.6	0